Drugs / PB1046
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03315507 | Oct 2017 → Aug 2019 | pulmonary arterial hypertension | PhaseBio Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02808585 | Jun 2016 → Dec 2017 | heart failure | PhaseBio Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PB1046 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03315507 ↗ |
| Modality | Peptide | “A Sustained-Release Analogue of Vasoactive Intestinal Peptide” NCT03315507 ↗ |
| Route | Subcutaneous | “Four weekly subcutaneous injections of PB1046.” NCT02808585 ↗ |